DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Type 1 diabetes (Juvenile Diabetes) - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
Introduction
Type 1 Diabetes (Juvenile Diabetes) Overview
Therapeutics Development
Pipeline Products for Type 1 Diabetes (Juvenile Diabetes) - Overview
Pipeline Products for Type 1 Diabetes (Juvenile Diabetes) - Comparative Analysis
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics under Investigation by Universities/Institutes
Type 1 Diabetes (Juvenile Diabetes) Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Type 1 Diabetes (Juvenile Diabetes) - Products under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) - Products under Investigation by Universities/Institutes
Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
- AbGenomics International, Inc.
- Adocia
- AiCuris GmbH & Co. KG
- Alteogen Inc.
- Amarantus Bioscience Holdings, Inc.
- Ambrx, Inc.
- AntriaBio, Inc.
- Aphios Corporation
- APT Therapeutics, Inc.
- Araim Pharmaceuticals, Inc.
- Argos Therapeutics, Inc.
- Artery Therapeutics, Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Athersys, Inc.
- Axxam SpA
- Beta-Cell NV
- Biocon Limited
- Biodel Inc.
- Biogenomics Limited
- BioLineRx, Ltd.
- BioLingus AG
- BioTherapeutics Inc.
- Boehringer Ingelheim GmbH
- Caladrius Biosciences, Inc.
- Carlina Technologies SAS
- Cellectis S.A.
- Compugen Ltd.
- Daewoong Pharmaceutical Co., Ltd.
- Dance Biopharm Inc.
- Diabetology (Products) Ltd
- DiaMedica Inc.
- Diamyd Medical AB
- Diasome Pharmaceuticals, Inc.
- Dompe Farmaceutici S.p.A.
For more information visit http://www.researchandmarkets.com/research/7pdxvp/type_1_diabetes
